Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis

Laura F Dagley, Andrew Emili, Anthony W Purcell

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Multiple sclerosis (MScl) is an inflammatory-mediated demyelinating disorder most prevalent in young Caucasian adults. The various clinical manifestations of the disease present several challenges in the clinic in terms of diagnosis, monitoring disease progression and response to treatment. Advances in mass spectrometry-based proteomic technologies have revolutionized the field of biomarker research and paved the way for the identification and validation of disease-specific markers. This review focuses on the novel candidates discovered by the application of quantitative proteomics to relevant disease-affected tissues in both the human context and within the animal model of the disease known as experimental autoimmune encephalomyelitis (EAE). The role of targeted mass spectrometry approaches for biomarker validation studies, such as multiple reaction monitoring (MRM) will also be discussed.
Original languageEnglish
Pages (from-to)91 - 108
Number of pages18
JournalProteomics - Clinical Applications
Volume7
Issue number1-2
DOIs
Publication statusPublished - 2013

Cite this

@article{171af221dbe248e98c92ac83dc9b2a46,
title = "Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis",
abstract = "Multiple sclerosis (MScl) is an inflammatory-mediated demyelinating disorder most prevalent in young Caucasian adults. The various clinical manifestations of the disease present several challenges in the clinic in terms of diagnosis, monitoring disease progression and response to treatment. Advances in mass spectrometry-based proteomic technologies have revolutionized the field of biomarker research and paved the way for the identification and validation of disease-specific markers. This review focuses on the novel candidates discovered by the application of quantitative proteomics to relevant disease-affected tissues in both the human context and within the animal model of the disease known as experimental autoimmune encephalomyelitis (EAE). The role of targeted mass spectrometry approaches for biomarker validation studies, such as multiple reaction monitoring (MRM) will also be discussed.",
author = "Dagley, {Laura F} and Andrew Emili and Purcell, {Anthony W}",
year = "2013",
doi = "10.1002/prca.201200104",
language = "English",
volume = "7",
pages = "91 -- 108",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag GmbH & Co. KGaA",
number = "1-2",

}

Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. / Dagley, Laura F; Emili, Andrew; Purcell, Anthony W.

In: Proteomics - Clinical Applications, Vol. 7, No. 1-2, 2013, p. 91 - 108.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis

AU - Dagley, Laura F

AU - Emili, Andrew

AU - Purcell, Anthony W

PY - 2013

Y1 - 2013

N2 - Multiple sclerosis (MScl) is an inflammatory-mediated demyelinating disorder most prevalent in young Caucasian adults. The various clinical manifestations of the disease present several challenges in the clinic in terms of diagnosis, monitoring disease progression and response to treatment. Advances in mass spectrometry-based proteomic technologies have revolutionized the field of biomarker research and paved the way for the identification and validation of disease-specific markers. This review focuses on the novel candidates discovered by the application of quantitative proteomics to relevant disease-affected tissues in both the human context and within the animal model of the disease known as experimental autoimmune encephalomyelitis (EAE). The role of targeted mass spectrometry approaches for biomarker validation studies, such as multiple reaction monitoring (MRM) will also be discussed.

AB - Multiple sclerosis (MScl) is an inflammatory-mediated demyelinating disorder most prevalent in young Caucasian adults. The various clinical manifestations of the disease present several challenges in the clinic in terms of diagnosis, monitoring disease progression and response to treatment. Advances in mass spectrometry-based proteomic technologies have revolutionized the field of biomarker research and paved the way for the identification and validation of disease-specific markers. This review focuses on the novel candidates discovered by the application of quantitative proteomics to relevant disease-affected tissues in both the human context and within the animal model of the disease known as experimental autoimmune encephalomyelitis (EAE). The role of targeted mass spectrometry approaches for biomarker validation studies, such as multiple reaction monitoring (MRM) will also be discussed.

UR - http://onlinelibrary.wiley.com/doi/10.1002/prca.201200104/pdf

U2 - 10.1002/prca.201200104

DO - 10.1002/prca.201200104

M3 - Article

VL - 7

SP - 91

EP - 108

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 1-2

ER -